1. Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer

3. Topics of Discussion

4. ABC2/ABC3 Guidelines: Management of Postmenopausal HR-Positive MBC

5. Tamoxifen vs AIs in First-Line HR-Positive MBC

6. FALCON Trial Results Showed Improvement in PFS

8. FALCON Trial PFS: Fulvestrant 500 mg vs Anastrozole

9. Mechanisms of CDK4/6 Inhibition in Breast Cancer

11. First-Line PALOMA-1 Trial: PFS Results

12. First-Line PALOMA-2 Trial: PFS Results

13. First Line MONALEESA-2 Trial: PFS

16. Deciding When to Use CDK4/6 Inhibitors in First-Line Setting

17. Selecting Patients for Palbociclib Based on Visceral Metastases

18. When Should Palbociclib Be Used in Second-Line Setting?

19. Second-Line PALOMA-3 Trial: PFS Results

20. BOLERO-2: Benefit of Adding Everolimus to Exemestane

21. Endocrine Therapy vs Chemotherapy

22. Use of Palbociclib-Based Treatments

23. Recommended Palbociclib Dose Adjustments for Patients With Neutropenia

24. Impact of Quality of Life in Patients Receiving Palbociclib Combination Therapy

25. Concluding Remarks

26. Abbreviations